Anbio Biotechnology Class A Ordinary Shares
NNNNNASDAQHealthcare● Active
$18.13
$-4.86(-21.14%)
Market Cap$795747456
P/E Ratio—
52W High$55.65
52W Low$7.92
Anbio Biotechnology Class A Ordinary Shares（NNNN）· 损益表
年度 / 季度 / TTM 视图 · SEC 10-K 与 10-Q（经 FMP 聚合）· 可在下方切换周期与 M/B/T 单位。
FMP · NNNN · 截至 2026-06-08
财务报表
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $9.76M | $8.19M | $6.71M | $23.54M | $4.43M |
| Cost of Revenue | $1.25M | $2.30M | $3.35M | $10.98M | $1.89M |
| Gross Profit | $8.51M | $5.89M | $3.36M | $12.56M | $2.54M |
| Gross Margin %(computed) | 87.24% | 71.90% | 50.07% | 53.36% | 57.40% |
| Operating Expenses | |||||
| R&D Expenses | $0.23M | $0.45M | $0.13M | $0.20M | $0.00M |
| G&A Expenses | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Total Operating Expenses | $2.00M | $3.89M | $1.40M | $2.37M | $0.09M |
| Operating Income | $6.51M | $2.00M | $1.96M | $10.20M | $2.46M |
| Operating Margin %(computed) | 66.70% | 24.38% | 29.22% | 43.30% | 55.46% |
| Interest Income | $0.16M | $0.34M | $0.17M | $0.04M | $0.00M |
| Interest Expense | $0.00M | $0.00M | $0.00M | $0.01M | $0.00M |
| Income Before Tax | $7.23M | $2.37M | $2.25M | $10.01M | $2.54M |
| Income Tax Expense | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Net Income | $7.23M | $2.37M | $2.25M | $10.01M | $2.54M |
| Net Margin %(computed) | 74.06% | 28.99% | 33.58% | 42.52% | 57.26% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $0.16 | $0.06 | $0.02 | $0.07 | $0.03 |
| Wtd Avg Shares | 43.89M | 42.29M | 143.89M | 143.89M | 100.00M |
| EBITDA | $6.51M | $2.57M | $2.27M | $10.03M | $2.54M |
| EBITDA Margin %(computed) | 66.70% | 31.36% | 33.77% | 42.58% | 57.26% |
数据来源：Financial Modeling Prep · 最后更新：2026-06-08 · USD · M
深入了解Anbio Biotechnology Class A Ordinary Shares
关于Anbio Biotechnology Class A Ordinary Shares（NNNN）损益表
Anbio Biotechnology Class A Ordinary Shares（NNNN）损益表数据来源于SEC Form 10-K及10-Q申报文件。2025财年，NNNN实现营收$0.01B，毛利润$0.01B（毛利率87.24%），净利润$0.01B（净利率74.06%）。
常见问题
NNNN · 4 问Anbio Biotechnology Class A Ordinary Shares（NNNN）2025财年营收为$0.01B，同比up19.2%。
NNNN revenueNNNN salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08